Ac­tio locks in $55M Se­ries A raise to ad­vance rare dis­ease pipeline based on hu­man ge­net­ic plat­form

Ac­tio Bio­sciences has se­cured a Se­ries A raise worth $55 mil­lion to ad­vance its clin­i­cal pipeline in rare dis­eases, par­tic­u­lar­ly in pa­tients with ion chan­nel TR­PV4 mu­ta­tions.

The San Diego, CA-head­quar­tered com­pa­ny has three as­sets in its pipeline, led by its un­named pre­clin­i­cal small mol­e­cule pro­gram un­der in­ves­ti­ga­tion for Char­cot-Marie-Tooth dis­ease type 2C (CMT2C) and oth­er rare bone dis­eases. CMT2C is caused by mu­ta­tions in TR­PV4.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER